Recurrent acute myocarditis: An under-recognized clinical entity associated with the later diagnosis of a genetic arrhythmogenic cardiomyopathy

Pierre Ollitrault1*, Mayane Al Khoury1, Yann Troade2, Yoann Calcagno1, Laure Champ-Rigot1, Virginie Ferchaud1, Arnaud Pellissier1, Damien Legallais1, Paul Milliez1 and Fabien Labombarda1

1Department of Cardiology, Caen University Hospital, Caen-Normandy University, Caen, France, 2Department of Genetics, Caen University Hospital, Caen-Normandy University, Caen, France

Background: Myocardial inflammation has been consistently associated with genetic arrhythmogenic cardiomyopathy (ACM) and it has been hypothesized that episodes mimicking acute myocarditis (AM) could represent early inflammatory phases of the disease.

Objective: We evaluated the temporal association between recurrent acute myocarditis (RAM) episodes and the later diagnosis of a genetic ACM.

Materials and methods: Between January 2012 and December 2021, patients with RAM and no previous cardiomyopathy were included (Recurrent Acute Myocarditis Registry, NCT04589156). A follow-up visit including clinical evaluation, resting and stress electrocardiogram, cardiac magnetic resonance imaging, and genetic testing was carried out. Endpoints of the study was the incidence of both ACM diagnosis criteria and ACM genetic mutation at the end of follow-up.

Results: Twenty-one patients with RAM were included and follow-up was completed in 19/21 patients (90%). At the end of follow-up, 3.3 ± 2.9 years after the last AM episode, 14/21 (67%) patients with an ACM phenotype (biventricular: 10/14, 71%; left ventricular: 4/14, 29%) underwent genetic testing. A pathogenic or likely pathogenic mutation was found in 8/14 patients (57%), 5/8 in the Desmoplakin gene, 2/8 in the Plakophilin-2 gene, and 1/8 in the Titin gene. Family history of cardiomyopathy or early sudden cardiac death had a positive predictive value of 88% for the presence of an underlying genetic mutation in patients with RAM.
Conclusion: RAM is a rare entity associated with the latter diagnosis of an ACM genetic mutation in more than a third of the cases. In those patients, RAM episodes represent early inflammatory phases of the disease. Including RAM episodes in ACM diagnosis criteria might allow early diagnosis and potential therapeutic interventions.

KEYWORDS
recurrent acute myocarditis, arrhythmogenic cardiomyopathy, myocardial inflammation, ventricular arrhythmia, sudden cardiac death

Introduction

Arrhythmogenic cardiomyopathy (ACM) is a genetically-determined or acquired (e.g., cardiac sarcoidosis, Chagas disease, myocarditis etc.) arrhythmogenic disorder of the myocardium. Genetic ACM is the consequence of pathogenic variants in genes encoding for desmosomal and cytoskeleton proteins. Originally described as a right ventricular disease (arrhythmogenic right ventricular cardiomyopathy/dysplasia; ARVC), genetic ACM is increasingly recognized as a left or biventricular entity (1). Genetic ACM may manifest with various clinical presentations, with a pre-disposition to acute and chronic heart failure, atrial and ventricular arrhythmias or sudden cardiac death. Pathophysiology of genetic ACM at early stages remain widely unknown and, since the first pathological descriptions, myocardial inflammation has been consistently associated with ACM pathophysiology. However, the exact nature of their association remains complex and elusive (2–9). Some patients might experience recurrent episodes of chest pain with cardiac troponin elevation and signal abnormalities on cardiac magnetic resonance imaging (CMRi), labeled as recurrent acute myocarditis (RAM) or myocarditis-like syndrome. However, the temporal association between RAM episodes and the later diagnosis of a genetic ACM is unknown, especially in patients without previously known cardiomyopathy (10–14).

Therefore, we aimed to study the incidence of both ACM phenotype and ACM genetic mutation in a longitudinal cohort of patients with RAM episodes without previously known cardiomyopathy.

Materials and methods

Population screening

Between January 2012 and December 2021, we screened consecutive patients admitted to our tertiary university center for clinically-suspected acute myocarditis (AM), defined by at least one clinical presentation and one diagnostic criterion from the European Society of Cardiology diagnostic criteria (15). We performed a longitudinal analysis, both retrospectively by collecting previous episodes of AM (by the use of medical records) and prospectively (using the referring cardiologist follow-up). The collected study data included anamnestic and clinical findings, serum myocardial necrosis markers detection (troponin I), 12-lead electrocardiograms (ECGs), two-dimensional and Doppler echocardiogram, telemetry records, 24-hours Holter ECG and CMRi. A focus was made on family history regarding heart transplantation, sudden cardiac death before the age of 35-year-old, or any unexplained cardiomyopathy (i.e., not explained by ischemic, valvular, or hypertensive heart disease). No endomyocardial biopsy was routinely performed in our center.

Inclusion criteria

Patients were included in the present study in case of RAM, defined by more than one episode of AM requiring hospital admission. Index AM was defined as the first episode of AM. Patients were excluded in case of pre-existing cardiomyopathy or angiographically detectable coronary artery stenosis (≥50%). A follow-up program was carried out in patients with RAM, the last follow-up visit being at least 6 months after last RAM episode. Last follow-up visit included clinical examination, resting 12-lead ECG, 24-hour Holter monitoring, exercise test and CMRi. CMRi was performed on a 1.5-Tesla scanner (Magnetom Avanto, Siemens Medical Solutions, France). All patients underwent a dedicated study protocol for myocarditis, including balanced steady-state free precession sequences cine images for morpho-functional evaluation, T1-weighted turbo spin-echo sequences for detection of myocardial fat infiltration, triple inversion recovery sequences for detection of myocardial oedema and early and late gadolinium enhancement (LGE) detection, respectively 3 min and 15 min after contrast agent intravenous administration.
Study endpoints

The primary endpoint of this study was the incidence of ACM diagnosis criteria at the last follow-up visit, as defined by the Padua criteria for right, left, and biventricular ACM (16). The secondary endpoint of this study was the incidence of genetic mutation in the population of patients with RAM and at least one ACM criteria at the last follow-up visit.

Genetic testing

In patients with at least one diagnosis criteria of ACM at the end of follow-up, a genetic testing was performed using Next Generation Sequencing (NGS) method and analyzed with Genodiag. Sanger method was then used to validate the variant by NGS. The panel of genes analyzed was: ABCC9, ACAD9, ACTC1, ACTN2, ALPK3, ANKRD1, BAG3, CALR3, CAV3, CRYAB, CSRP3, CTNNAA3, DES, DSC2, DSG2, DSP, DTNA, EMD, EYA4, FBN1, FHL1, FLNC, GAA, GATA4, GLA, HCN4, HEY2, JPH2, Kras, LAMA4, LAMP2, LDB3 (ZASP), LMANA, MYBP3, MYH6, MYH7, MYL2, MYLK2, MYOM1, MYOZ2, MYZP1, NEXN, NKX2-5, PDLIM3, PKP2, PLN, PRDM16, PRKAG2, PTEN11, RAF1, RBM20, RYR2, SCN5A, SDHA, SGCD, SLCL25A4, SOS1, SYNPO2, TAZ, TCAP, TMEM43, TMPO, TNCC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL. Pathogenicity of variants was classified according to current guidelines (grade IV being likely pathogenic and grade V being pathogenic).

Statistical analysis

Data are presented as mean ± standard deviation or median (quartile 1–quartile 3) as appropriate, and categorical variables are given as number of patients with the attribute (percentage). For continuous variables, Student’s t-test or a Mann-Whitney U test, as appropriate, was performed for comparison between two groups. The Chi-square test was used for analysis of categorical variables. A p < 0.05 denoted statistical significance. Analyses and figures were conducted using IBM SPSS Statistics for Macintosh (Version 25.0, IBM, Chicago, Illinois).

Ethics

The study protocol was compliant with the STROBE statement and registered as a clinical trial (Recurrent Acute Myocarditis Registry NCT04589156). Approval for this study was obtained from the local Ethics Committee and was in accordance with the declaration of Helsinki.

Results

Population

Between January 2012 and December 2021, a total of 21 patients (16 male; 76%) with RAM were included. Characteristics of patients, index AM, and first RAM are detailed in Table 1. No patients had a previous personal history of cardiomyopathy or ventricular arrhythmia. Five (24%) patients had a first-degree family history (genetic cardiomyopathy or ventricular arrhythmia or sudden cardiac death) and one (4.8%) patient had a non-first-degree family history (heart transplantation in a 4th degree relative). For one patient (4.8%) father-related family history was not available. Eighteen (86%), two (9.5%), and one (4.8%) patients experienced, respectively two, three, and five RAM episodes (accounting for a total of 47 AM episodes). The median age at the time of index and first recurrence was, respectively 23 [19–41] and 29 [21–44] year-old. The median time duration between index and first recurrence was two [1–5] years. Considering index AM and first RAM (42 episodes), clinical presentation was pseudo-acute coronary syndrome (ACS) and palpitations in respectively, 16/42 (38%) and 12/42 (29%) episodes. Acute ST segment elevation and T-wave inversion were present in respectively, 11/42 (26%) episodes. Sustained ventricular arrhythmia was found in 2/42 (4.8%) episodes. LGE was found in 33/42 (79%) episodes, 32/33 (99%) involving the subepicardial layer of the left ventricular lateral wall.

Development of an arrhythmogenic cardiomyopathy phenotype at the end of follow-up

Follow-up was completed in 19/21 patients (90%), 3.3 ± 2.9 years after the last episode of AM. Clinical, resting, and stress ECG and CMRi data at the end of follow-up are detailed in Table 2. Considering the 19 patients with complete follow-up, 14/19 (74%) developed an ACM phenotype according to the Padua criteria, the remaining 5/19 (26%) being free of cardiovascular abnormalities. None of the patients developed extracardiac signs of sarcoidosis. Among the 14 patients with an ACM phenotype, left ventricular, or biventricular forms were found respectively, in 10/14 (71%) and 4/14 (29%) patients. Major criteria for left ventricular structural abnormalities were most commonly found (14/14; 100%), followed by left ventricular morphofunctional abnormalities (5/14; 36%), right ventricular repolarization abnormalities (3/14; 21%), and right ventricular morphofunctional abnormalities (3/14; 21%).
| Pt# | Family history | Age (y–0) | Clinical presentation | ECG | CMR | Age (y–0) | Clinical presentation | ECG | CMR | Other AM |
|-----|----------------|-----------|-----------------------|-----|-----|-----------|-----------------------|-----|-----|---------|
| 1   | 0              | 20        | Pseudo-ACS, Rhinitis  | Diffuse ST elevation | LGE inferolateral (subepi) | 22 | Pseudo-ACS | TWI V4–V6 | LGE lateral (subepi) |
| 2   | 0              | 43        | Pseudo-ACS            | TWI inferolateral | LGE inferolateral basal & median | 44 | Pseudo-ACS | TWI inferolateral | LGE inferolateral basal |
| 3   | 0              | 11        | Pseudo-ACS            | Diffuse ST elevation | LGE lateral (subepi) | 12 | Pseudo-ACS | Normal | LGE inferolateral (subepi) |
| 4   | 0              | 60        | Pseudo-ACS            | Normal | LGE lateral apical (subepi) | 61 | Pseudo-ACS | Normal | LGE lateral basal (subepi) |
| 5   | Brother SCD    | 31        | Pseudo-ACS            | TWI V1–V2 | LGE lateral (subepi), RV inferolateral dyskinesia | 32 | Pseudo-ACS | TWI V1–V2±V3 | LGE inferior median, lateral basal (subepi), RV dyskinesia |
| 6   | Mother HCM     | 14        | Pseudo-ACS            | Normal | LGE inferolateral median & apical (subepi) | 14 | Pseudo-ACS | Normal | LGE inferolateral basal (subepi) |
| 7   | Mother DCM and ICD | 17      | Pseudo-ACS            | LV anterior PVCs | LGE anterolateral (subepi), LVEF 45% | 19 | Pseudo-ACS | LV anterior PVCs | LGE anterolateral LVEF 28% |
| 8   | 0              | 49        | Pseudo-ACS            | Normal | LGE anterolateral medial (subepi) | 52 | Pseudo-ACS | Diffuse ST elevation | No LGE Pericardial effusion |
| 9   | 0              | 18        | Pseudo-ACS            | Diffuse ST elevation | No LGE | 21 | Pseudo-ACS | Normal | No LGE LVEF 45% |
| 10  | 0              | 49        | Pseudo-ACS            | Normal | No CMR (normal coronary angiography) | 54 | Pseudo-ACS, Fever | Diffuse ST elevation, TWI V3–V6, DI aVL | LGE lateral apical (subepi), LVEF 49% |
| 11  | 0              | 28        | Pseudo-ACS            | Diffuse ST elevation | LGE inferior basal | 35 | Pseudo-ACS, Vaccine | Diffuse ST elevation | LGE multifocal, RVEF 48%, LVEF 35% |
| 12  | 0              | 55        | Bronchitis, Palpitations | TWI inferior Left VT | LGE inferior basal (subepi), LVEF 45% | 56 | Pseudo-ACS | TWI inferior Left VT | LGE inferolateral basal (subepi), inferior RV |
| 13  | 0              | 23        | PVCs                  | TWI inferolateral | LGE inferior basal & median (subepi), LVEF 53%, Pericardial effusion | 24 | Pseudo-ACS | Anterior ST elevation | LGE inferolateral basal (subepi), anterior apical (subepi) |
| 14  | 0              | 20        | Pseudo-ACS            | Diffuse ST elevation | LGE lateral apical (subepi) | 29 | Pseudo-ACS | Normal | LGE lateral apical (subepi) |
| 15  | Son AM Mother SCD | 27     | Pseudo-ACS            | Lateral ST elevation | No CMR (normal coronary angiography) | 44 | Pseudo-ACS | TWI lateral | LGE anterolateral (subepi), inferior (subepi) |
| 16  | Sister HTx     | 41        | Pseudo-ACS            | Normal | No CMR (normal coronary angiography) | 51 | Pseudo-ACS | Lateral ST elevation, NSVT | LGE multifocal, LVEF 34% |
| 17  | 0              | 19        | Pseudo-ACS, Fever     | Diffuse ST elevation | LGE inferolateral median (subepi) | 31 | Pseudo-ACS, Amygdalitis | Diffuse ST elevation | LGE anterolateral median & apical (subepi), LVEF 47% |

(Continued)
Prevalence of genetic mutations in recurrent acute myocarditis with arrhythmogenic cardiomyopathy phenotype

According to study protocol, 14 patients with an ACM phenotype at the end of follow-up underwent genetic testing. A pathogenic (i.e., grade V) or likely pathogenic (i.e., grade IV) mutation was found in 8/14 (57%) patients. Gene mutations were most frequently found in the Desmoplakin (DSP) gene (5/8; 63%), followed by the Plakophilin-2 (PKP2) gene (2/8; 25%), and the Titin (TTN) gene (1/8; 13%). DSP p.Glu1343Asnsfs*, DSP p.3082_3084 + 13del, DSP p.3403C>T, DSP c.2588T>C, DSP c.5028_5031del, PKP2 c.1132C>T (two patients from same family, brother, and sister), and TTN c.14372-2A>G. In patient #12, an additional mutation of unknown significance was found in BCL2-associated athanogene-3 (BAG3) gene.

Considering the 14 patients with RAM and ACM phenotype at the end of follow-up, family history had a sensitivity of 88% and a positive predictive value of 100% for the presence of an underlying genetic mutation. An illustrative example of a patient (number 5) with RAM, ACM phenotype, and DSP mutation is illustrated in Figure 1. A proposed model for the association between RAM and genetic ACM is illustrated in Figure 2.

Discussion

The main findings of this study can be summarized as follows: (1) collecting data from a unique and large cohort of patients with RAM and no previous history of cardiomyopathy, we found that an ACM phenotype develops in more than 2/3rd of cases during follow-up; (2) in those patients, we found a high prevalence of previously unknown genetic mutation, illustrating the fact that that RAM represents the early phenotypic expression of a genetic ACM related to desmosomal or cytoskeleton gene mutations.

The (under-recognized) genetic background of acute myocarditis

In the vast majority of patients, AM is an acquired cardiac disease related to a viral infection and/or an autoimmune process. It is a major cause of sudden cardiac death in young adults (17) but also a predictor of long-term adverse outcome: Grün et al. found a 19% mortality at 5 year after a biopsy proven viral myocarditis (18) and, from a large insurance database, Te et al. found a 5.4% risk of VT and a 6.5% risk of cardiovascular death at 10 years after an AM (19). RAM,
### TABLE 2 Follow-up of patients with recurrent acute myocarditis (RAM) (n = 21).

| Pt# | Family history | Age (y–0) | Clinical presentation | Resting ECG | Exercise ECG | CMRI | ACM criteria | Genetic testing? | Genetic mutation (Grade) |
|-----|----------------|-----------|-----------------------|-------------|--------------|------|--------------|------------------|-----------------------|
|     |                |           |                       |             |              |      | Right        |                  |                       |
| 1   |                | 26        | Normal                | Normal      | Normal       | LGE lateral apical | 0   | 1M 0m       | Yes              | 0                     |
| 2   | 0              | 46        | Dyspnea               | SND, 1st degree AVB, iRBBB | Left PVCs | LGE lateral basal | 0   | 1M 1m       | Yes              | 0                     |
| 3   | 0              | 13        | Normal                | Normal      | Normal       | Not done | 0   | 0           | No               | –                     |
| 4   | 0              | 67        | Normal                | Normal      | Normal       | Normal | 0   | 0           | No               | –                     |
| 5   | Brother SCD    | 35        | TWI VI–V4             | Right PVCs | RV EDV 108 ml/m² and RVOT dyskinesia, LGE inferior median | 2M 1m | 1M 0m | Yes | DSP p.Gln343Asnfs* (IV) |
|     | Mother HCM     |           |                       |             |              |        | 2M 0m       | Yes              | 0                     |
| 6   | 0              | 22        | Normal                | Normal      | PVCs         | LGE inferolateral median, LVEF 49% | 0   | 2M 0m       | Yes              | 0                     |
| 7   | Mother DCM and ICD | 24 | Palpitations                  | Paroxysmal AF | Left PVCs | LGE inferior basal median and anterolateral median, LVEF 28% | 0   | 2M 0m       | Yes | DSP c.3082_3084+13del (IV) |
| 8   | 0              |           |                       |             |              |        | No follow-up data |                  |                       |
| 9   | 0              | 23        | Normal                | Normal      | Normal       | Normal | 0   | 1M 0m       | Yes              | 0                     |
| 10  | 0              | 69        | Dyspnea               | Normal      | Normal       | Normal | 0   | 1M 0m       | Yes              | 0                     |
| 11  | 0              | 35        | Chest pain            | Normal      | Normal       | LGE inferolateral basal, septal median | 0   | 1M 0m       | Yes              | 0                     |
| 12  | 0 (unknown father) | 63 | TWI inferior Microvoltage | PVCs | LGE inferolateral basal, LVEF 50% LGE inferior RV | 1M 0m | 2M 2m | Yes | DSP C.3403OT (IV)/BAG3 C.155OG (III) |
| 13  | 0              | 25        | RV5 inferolateral Microvoltage | Normal | LGE lateral basal & apical and anterior apical | 0   | 1M 0m       | Yes              | 0                     |
| 14  | 0              | 29        | Normal                | Normal      | Normal       | Normal | 0   | 0           | No               | –                     |
| 15  | Son AM Mother SCD Uncle HTx | 49 | Palpitations                  | Normal      | Normal       | LGE lateral median, LVEF 46% | 0   | 2M 0m       | Yes | DSP c.2588T>C (IV) |
| 16  | Sister HTx     | 53        | Normal                | Left PVCs  | LGE multifocal, LVEF 49% | 0   | 2M 0m       | Yes              | DSP c.5028_5031del (IV) |
| 17  | Sister ACM/PKP2* | 36 | Normal                | Normal      | Normal       | Normal | 0   | 0           | No               | –                     |
| 18  | Brother ACM/PKP2* | 23 | TWI VI–V2 NSVT | Normal | LGE lateral median RVOT hypokinesia, RVEF 30% | 2M 1m | 1M 0m | Yes | PKP2 c.1132C>T (V) |
| 19  | Brother ACM/PKP2* | 32 | TWI VI–V6 Right PVCs | LGE inferior median RV EDV 105 ml/m², RVEF 44% | 2M 1m | 1M 0m | Yes | PKP2 c.1132C>T (V) |
| 20  | HTx (4th degree) | 24        | Normal                | Normal      | Normal       | LGE inferolateral basal & median | 0   | 1M 0m       | Yes | TTN c.14372-2A>G (IV) |
| 21  | 0              |           |                       |             |              |        | No follow-up data |                  |                       |

For abbreviations see Table 1.
26 year-old: palpitations, left PVCs, TWI $V_1$, $V_2$, normal TTE (no CMRi)
Asymptomatic on Nadolol

31 year-old: index AM, pseudo-ACS, TWI $V_1$, $V_2$, LGE lateral subepi, RV inferolateral dyskinesia

32 year-old: RAM, pseudo-ACS, TWI $V_1$, $V_2$, LGE inferior median subepi, lateral basal, RV inferolateral dyskinesia

33 year-old: normal cardiac PET-TDM

37 year-old: last follow-up, asymptomatic, TWI $V_1$ – $V_6$, RV EDV 108ml/m2, RVOT dyskinesia and inferolateral dyskinesia, LGE inferior median

DSP p.Glu1343Asnfs* (IV)

FIGURE 1
Representative example of a patient (Pt#5) with recurrent acute myocarditis (RAM), arrhythmogenic cardiomyopathy (ACM) phenotype, and Desmoplakin (DSP) mutation.
defined as more than one episode of AM, has been the subject of very few case reports, and we describe here the largest cohort using a longitudinal analysis of a tertiary referral center population. The genetics of AM are complex, but recently Brown et al. identified genetic mutations in pediatric cases of acute heart failure presumed to be myocarditis, affecting TNNT2, MYBPC3, and TTN genes (20). Individuals with a genetic mutation tended to have poor outcomes, such as cardiac transplantation or cardiovascular death. Those findings were corroborated by Seidel et al. (21), which found genetic variants in DSP, TTN, and other genes in 22% of biopsy-proven pediatric myocarditis. Additionally, Piriou et al. found that in patients with AM and a family history of cardiomyopathy or sudden cardiac death, genetic testing revealed gene mutations during family screening (14). In our study, we found that more than approximately one third of patients with RAM had a previously unknown pathogenic or likely pathogenic mutation, mostly affecting the DSP gene. Recently, Ader et al. found a prevalence of genetic variants of 56% in patients with a single AM and ventricular arrhythmia or right ventricular abnormalities during follow-up (11). Altogether, those data support the fact that genetic background is a key player in AM pathogenesis, and that AM must not be considered solely as an acquired cardiovascular disease. Those data also underline the necessity of prolonged follow-up for AM patients, searching for an ACM phenotype and an underlying genetic mutation. Importantly, we found a significant proportion of patients with RAM, ACM phenotype, and without genetic mutation (6/14, 43%). Those patients might have what could be defined as “true” post-myocarditis acquired ACM, with persistent left ventricular scarring. The prognosis of such condition needs to be evaluated by a dedicated study.

The role of inflammation in genetic arrhythmogenic cardiomyopathy

Myocardial inflammation is a common feature in genetic ACM but the exact nature of their association remains elusive (2, 3). Inflammatory infiltrates are found in approximately 80% of genetic right ventricular ACM (i.e., ARVC) using post-mortem histological analysis (4). Moreover, 36% of patients with genetic right ventricular ACM have active myocardial inflammation on 18F-Fluorodeoxyglucose positron emission tomography (5). The exact mechanism of myocardial inflammation remains speculative, although evidence of myocardial auto-immunity has been found in the majority of genetic right ventricular ACM, due to auto-heart antibodies (6, 7). The proportion of patients with a clinical expression of myocardial inflammation (i.e., AM episodes) seems to be lower than the reported prevalence using non-invasive imaging or histological studies. In a cohort of 131 patients affected with genetic ACM (both right and left ventricular ACM), Lopez-Ayala et al. found a 4.5% prevalence of AM episode (10). Altogether, those data
support the hypothesis of myocardial inflammation being a key pathophysiological component of genetic ACM. However, the factors favoring a clinically-over myocardial expression during the early phases of genetic ACM remain widely elusive. Clinical episodes of myocardial inflammation, mimicking AM, might be the consequence of both genetic and environmental factors. The prevalence of AM episode has been reported to be higher in case of DSP mutation (15%) (12), which is in line with our findings as DSP mutations were over-represented in patients with RAM and ACM phenotype. An infectious trigger might also explain an inflammatory expression in case of desmosomal gene mutation, as adenovirus or enterovirus DNA could be found in up to half of the case of right ventricular ACM using PCR on endomyocardial biopsy samples in previous studies (8, 9). Finally, Martins et al. found that, in patients with genetic ACM and previous AM episode(s), 50% of those episodes were exercise-triggered (22). This finding corroborates the fact that intense exercise increases age-related penetration and arrhythmogenic risk in genetic ACM (23), but also the risk of adverse outcome after AM (24, 25). Finally, our work underlines the important dynamicity of myocardial inflammation in the early phase of genetic ACM, as most patients had dynamic changes in TWI and/or LGE during time (which is rather unusual in the late phase of genetic ACM). The complex interaction between genetic and non-genetic factors is a call for larger multicentric studies.

Recurrent acute myocarditis: A new diagnosis criterion for genetic arrhythmogenic cardiomyopathy?

As discussed above, RAM and genetic ACM share common genetic and pathophysiological backgrounds, and we proposed a model linking those two entities (Figure 2). In our study, we found that the combination of RAM, ACM phenotype, and family history had a high positive predictive value for the presence of an underlying genetic mutation, confirming a posteriori the final diagnosis of genetic ACM (either left sided or biventricular). Therefore, implementation of AM episode(s) in the current criteria for genetic ACM diagnosis (1, 16) might allow a definite diagnosis in the early phase of the disease, when otherwise it is borderline using conventional criteria. Indeed, RAM and ACM criteria remain highly aspecific diagnostic criteria which can encountered in several other diseases than genetic ACM (sarcoidosis, Chagas disease, hypertrophic cardiomyopathy, etc.). However, our work support the fact that those aspecific anomalies, when associated together, justify genetic testing to establish a definite diagnosis of genetic ACM. Allowing an early diagnosis during the natural history of genetic ACM might offer the possibility to target myocardial inflammation, in order to improve penetrance and arrhythmogenic risk of the disease, but the therapeutic options need to be studied.

Limitations

Our study is an observational longitudinal study, and therefore might suffer from selection bias. However, our center is the only tertiary referral center for AM, ACM, and genetic myocardial diseases for a population of 1.5 million inhabitants, which might have limited the impact of such bias. The small sample size of our cohort makes our findings exploratory. Even though we present here the largest cohort of RAM patients, those findings needs to be validated in larger multicentric studies, in order to allow multivariable statistical analysis. The fact that genetic testing was not performed in RAM patients without ACM criteria is another reason potentially leading to an underestimation of genetic mutation prevalence. However, without an arrhythmogenic phenotype, the clinical relevance of finding a mutation in a RAM patients would be limited regarding current knowledge. No systematic endomyocardial biopsy was performed in our patients, which might be considered as a limitation to label those episodes of chest, troponin elevation and CMRi abnormalities as “true” AM. However, the diagnostic yield of EBM is variable in both AM and ACM, due to patchy substrate, left ventricular, and/or subepicardial localization. In fact, histological diagnosis criteria for AM and ACM are nowadays frequently replaced by non-invasive tissular characterization by CMRi (15, 16).

Conclusion

RAM is an under-recognized entity associated with the latter diagnosis of a genetically-determined ACM in more than a third of the cases. In those patients, RAM episodes represent early, paroxysmal, inflammatory phases of the disease. Genetic and environmental factors leading to a clinically-over inflammatory expression of genetic ACM remain to be studied. AM episodes may justify a systematic genetic testing, especially in the presence of a suspicious family history.

Data availability statement

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Evidences from family studies for autoimmunity in arrhythmogenic right ventricular cardiomyopathy.

Caforio ALP, Re F, Avella A, Marcolongo R, Baratta P, Seguso M, et al. Genetics of myocarditis in 2003.12.056

References

1. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmicogenic cardiomyopathy. Heart Rhythm. (2019) 16:301–72.

2. Bauce B, Basso C, Rampazzo A, Befagna G, Daliento L, Frigo G, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. (2005) 26:1666–75. doi: 10.1093/eurheartj/hh341

3. Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiovasc Pathol. (2006) 15:11–7. doi: 10.1016/j.carpath.2005.10.004

4. Burke AP, Farb A, Tashki G, Virmani R. Arhythmmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium. Are they different diseases? Circulation. (1998) 97:1571–80.

5. Protonarios A, Wicks E, Stephenson E, Guttmann O, Savvatis K, et al. Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. (2019) 284:99–104. doi: 10.1016/j.ijcard.2018.10.083

6. Chatterjee D, Fatmah M, Aldis D, Spears DA, Koopmann TT, Mittal K, et al. An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis. Eur Heart J. (2018) 39:3932–44. doi: 10.1093/eurheartj/ehy567

7. Caforio ALP, Re F, Avella A, Marcolongo R, Baratta P, Seguso M, et al. Evidence from family studies for autoimmunity in arrhythmogenic right ventricular cardiomyopathy: associations of circulating anti-heart and anti-intercalated disk autoantibodies with disease severity and family history. Circulation. (2020) 141:1238–48. doi: 10.1161/CIRCULATIONAHA.119.038416

8. Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotoxic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardio myopathy. J Am Coll Cardiol. (2002) 39:892–5.

9. Chimenti C, Pieroni M, Maeser A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. (2004) 43:2305–13. doi: 10.1016/j.jacc.2003.12.056

10. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. (2015) 12:766–73.

11. Ader E, Surget E, Charron P, Redheuil A, Zouaghi A, Malfret A, et al. Inherited cardiomyopathies revealed by clinically suspected myocarditis: highlights from genetic testing. Circ Genes Med. (2020) 13:e002744. doi: 10.1161/CIRCGEN.119.002744

12. Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. Desmplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation. (2020) 141:1872–84.

13. Belkaya S, Kontorovich AR, Byun M, Muleros-Navarro S, Bajolet F, Cobat A, et al. Autosomal recessive cardiomyopathy presenting as acute myocarditis. J Am Coll Cardiol. (2017) 69:1653–65. doi: 10.1016/j.jacc.2017.01.043

14. Piriou N, Marteau L, Kyndt F, Sarfathy JM, Toquet C, Le Gloan L, et al. Familial screening in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies. ESC Heart Fail. (2020) 4:1520–1533. doi: 10.1002/ehj2.12686

15. Caforio ALP, Pankriwte S, Aribustini E, Basso C, Gimenov-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. (2013) 34:2636–48. doi: 10.1093/eurheartj/eht120

16. Corrado D, Marra MP, Zorzi A, Befagna G, Cipriani A, De Lazzari MD, et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol. (2020) 319:106–14.

17. Bagdall RD, Weintraub RG, Ingles J, Duffouf J, Yeates L, Lam L, et al. A prospective study of sudden cardiac death among children and adults. N Engl J Med. (2016) 374:2441–52.

18. Grun S, Schummm J, Gereau C, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis. J Am Coll Cardiol. (2012) 59:1604–15.

19. Te AL, Wu TC, Lin YJ, Chen YY, Chung FP, Chang SL, et al. Increased risk of ventricular tachycardia and cardiovascular death in patients with myocarditis during the long-term follow-up. A national representative cohort from the national health insurance research database. Medicine. (2017) 96:6633. doi: 10.1097/MD.000000000006663

20. Brown EE, McMillan KN, Halushka MK, Ravekes WJ, Knight M, Crosson JE, et al. Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis. Cardiol Young. (2019) 29:917–21. doi: 10.1017/S1047951119001124

21. Seidel F, Holfgewe M, Bakker-Marquard N, Oppen-Rhein B, Dartsch J, Herbst C, et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in pediatric myocarditis. Circ Genes Med. (2021) 14:e003250. doi: 10.1161/CIRCGEN.120.003250

Author contributions

PO, PM, and FL elaborated the study protocol. PO, MA, and YC collected the study data and performed statistical analysis, and drafted the manuscript. All authors critically reviewed the manuscript.

Ethics statement

The studies involving human participants were reviewed and approved by Comité Local d’Ethique sur la Recherche en Santé (CLERS). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
22. Martins D, Ovaert C, Khraiche D, Boddaert N, Bonnet D, Raimondi F. Myocardial inflammation detected by cardiac MRI in arrhythmogenic right ventricular cardiomyopathy: a pediatric case series. *Int J Cardiol.* (2018) 271:81–6. doi: 10.1016/j.ijcard.2018.05.116

23. James CA, Bhonsale A, Tichnell C, Murray B, Russel SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy-associated desmosomal mutation carriers. *J Am Coll Cardiol.* (2013) 62:1290–7. doi: 10.1016/j.jacc.2013.06.033

24. Cabinian AE, Kiel RJ, Smith E, Ho KL, Khatib R, Reyes MP. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model. *J Lab Clin Med.* (1990) 115:454–62.

25. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the sport cardiology section of the European association of preventive cardiology (EAPC). *Eur Heart J.* (2019) 40:19–33. doi: 10.1093/eurheartj/ehy730